Last reviewed · How we verify
NCT04282434: CLEOPAHTRA
DNA Methylation Dynamics Underlying Arterial Remodeling in PAH Patients: CLEOPAHTRA Clinical Trial
trial in Pulmonary Arterial Hypertension in 30 participants. Completed in 14 October 2020.
14 June 2020
Quick facts
| Lead sponsor | University of Campania Luigi Vanvitelli |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 14 June 2019 |
| Primary completion | 14 June 2020 |
| Estimated completion | 14 October 2020 |
| Sites | 1 location across Italy |
Conditions studied
- Pulmonary Arterial Hypertension — all drugs for Pulmonary Arterial Hypertension →
- Pulmonary Arterial Remodeling — all drugs for Pulmonary Arterial Remodeling →
Sponsor
University of Campania Luigi Vanvitelli
Who can join
Adults 18 to 75, any sex, with Pulmonary Arterial Hypertension or Pulmonary Arterial Remodeling. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To identify epigenetic-sensitive modifications and novel biomarkers linked to pathogenesis of pulmonary arterial hypertension (PAH), we will perform the first study analyzing differentially-methylated regions (DMRs) in circulating T cells (CD04+ and CD08+) isolated from peripheral blood of patients undergoing right heart catheterization. Moreover, we will perform RNA deep sequencing on lung tissue biopsies to validate if DNA methylation signatures in circulating T cells could reflect perturbations of gene expression in lung tissues.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials.
Shi Y, Zhang H, Huang S, Yin L, et al · · 2022 · cited 233× · PMID 35752619 · DOI 10.1038/s41392-022-01055-2 -
Association Between Circulating CD4<sup>+</sup> T Cell Methylation Signatures of Network-Oriented SOCS3 Gene and Hemodynamics in Patients Suffering Pulmonary Arterial Hypertension.
Benincasa G, Maron BA, Affinito O, D'Alto M, et al · · 2023 · cited 35× · PMID 35960497 · DOI 10.1007/s12265-022-10294-1
Verify or expand the search:
- PubMed search for NCT04282434
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pulmonary Arterial Hypertension
Currently open trials in the same condition.
- NCT07391228 — Cognitive Alterations in Pulmonary Arterial Hypertension (PAH) · active not recruiting
- NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
- NCT07217522 — Rutgers University Study of the Genetics of Pulmonary Hypertension · recruiting
- NCT07013149 — The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension · recruiting
- NCT06658522 — Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effec · Phase 4 · recruiting
Other University of Campania Luigi Vanvitelli trials
Trials by the same sponsor.
- NCT07590349 — Personalized Robotic Telerehabilitation for Upper Limb Functional Recovery After Stroke in a Home-Based Setting · NA · not yet recruiting
- NCT06718452 — Tinnitus and Treatment With umPEA-LUT · NA · not yet recruiting
- NCT07124676 — Prospective Study Comparing Two Classification Systems for Second-degree Vaginal Tears During Spontaneous Childbirth to · not yet recruiting
- NCT07425912 — Real-World Evaluation of TouchCare Nano in Pediatric Type 1 Diabetes · active not recruiting
- NCT06991816 — The Brain&Senses Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04282434 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Campania Luigi Vanvitelli
- Last refreshed: 14 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04282434.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing